@article {Jouan2020.05.03.20089300, author = {Youenn Jouan and Antoine Guillon and Lo{\"\i}c Gonzalez and Yonatan Perez and Stephan Ehrmann and Marion Ferreira and Thomas Daix and Robin Jeannet and Bruno Fran{\c c}ois and Pierre-Fran{\c c}ois Dequin and Mustapha Si-Tahar and Thomas Baranek and Christophe Paget}, title = {Functional alteration of innate T cells in critically ill Covid-19 patients}, elocation-id = {2020.05.03.20089300}, year = {2020}, doi = {10.1101/2020.05.03.20089300}, publisher = {Cold Spring Harbor Laboratory Press}, abstract = {Covid-19 can induce lung infection ranging from mild pneumonia to life-threatening acute respiratory distress syndrome (ARDS). Dysregulated host immune response in the lung is a key feature in ARDS pathophysiology. However, cellular actors in Covid-19-driven ARDS are poorly understood. Here, we dynamically analyzed the biology of innate T cells, a heterogeneous class (MAIT, γδT and iNKT cells) of T lymphocytes, presenting potent anti-infective and regulatory functions. Patients presented a compartmentalized lung inflammation paralleled with a limited systemic inflammation. Circulating innate T cells of critically ill Covid-19 patients presented a profound and persistent phenotypic and functional alteration. Highly activated innate T cells were detected in airways of patients suggesting a recruitment to the inflamed site and a potential contribution in the regulation of the local inflammation. Finally, the expression of the CD69 activation marker on blood iNKT and MAIT cells at inclusion was predictive of disease severity. Thus, patients present an altered innate T cell biology that may account for the dysregulated immune response observed in Covid-19-related acute respiratory distress syndrome.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT03379207Funding StatementThis work was supported by the Inserm, CHRU Tours, University of Tours, the Agence Nationale de la Recherche {\textquotedblleft}JCJC program{\textquotedblright} (ANR-19-325 CE15-0032-01) and by the Fondation du Souffle, with the {\textquotedblleft}Fond de recherche en Sant{\'e} Respiratoire{\textquotedblright}.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data referred to in the manuscript are available upon request to christophe.paget{at}inserm.fr}, URL = {https://www.medrxiv.org/content/early/2020/05/06/2020.05.03.20089300}, eprint = {https://www.medrxiv.org/content/early/2020/05/06/2020.05.03.20089300.full.pdf}, journal = {medRxiv} }